Femasys | 10-Q: FY2025 Q3 Revenue Misses Estimate at USD 729.39 K

LB filings
2025.11.14 21:22
portai
I'm PortAI, I can summarize articles.

Revenue: As of FY2025 Q3, the actual value is USD 729.39 K, missing the estimate of USD 1.35 M.

EPS: As of FY2025 Q3, the actual value is USD -0.1, beating the estimate of USD -0.115.

EBIT: As of FY2025 Q3, the actual value is USD -3.139 M.

Financial Metrics by Segment

Segment Revenue

  • Sales: $729,394 for the three months ended September 30, 2025, compared to $554,908 for the same period in 2024, representing a 31.4% increase.
  • Sales: $1,479,926 for the nine months ended September 30, 2025, compared to $1,047,532 for the same period in 2024, representing a 41.3% increase.

Operational Metrics

  • Cost of Sales: $293,838 for the three months ended September 30, 2025, compared to $190,839 for the same period in 2024, representing a 54.0% increase.
  • Cost of Sales: $569,275 for the nine months ended September 30, 2025, compared to $352,496 for the same period in 2024, representing a 61.5% increase.
  • Research and Development Expenses: $1,382,022 for the three months ended September 30, 2025, compared to $2,303,241 for the same period in 2024, representing a 40.0% decrease.
  • Research and Development Expenses: $5,764,923 for the nine months ended September 30, 2025, compared to $6,049,847 for the same period in 2024, representing a 4.7% decrease.
  • Sales and Marketing Expenses: $1,143,805 for the three months ended September 30, 2025, compared to $1,572,189 for the same period in 2024, representing a 27.2% decrease.
  • Sales and Marketing Expenses: $3,037,349 for the nine months ended September 30, 2025, compared to $2,847,866 for the same period in 2024, representing a 6.7% increase.
  • General and Administrative Expenses: $1,477,800 for the three months ended September 30, 2025, compared to $1,530,791 for the same period in 2024, representing a 3.5% decrease.
  • General and Administrative Expenses: $4,817,485 for the nine months ended September 30, 2025, compared to $4,645,412 for the same period in 2024, representing a 3.7% increase.
  • Depreciation and Amortization: $85,697 for the three months ended September 30, 2025, compared to $76,288 for the same period in 2024, representing a 12.3% increase.
  • Depreciation and Amortization: $256,835 for the nine months ended September 30, 2025, compared to $215,144 for the same period in 2024, representing a 19.4% increase.
  • Net Loss: $4,194,821 for the three months ended September 30, 2025, compared to $5,408,860 for the same period in 2024, representing a 22.4% decrease.
  • Net Loss: $14,677,582 for the nine months ended September 30, 2025, compared to $13,692,944 for the same period in 2024, representing a 7.2% increase.

Cash Flow

  • Net Cash Used in Operating Activities: $14,505,325 for the nine months ended September 30, 2025, compared to $14,369,440 for the same period in 2024.
  • Net Cash Used in Investing Activities: $433,383 for the nine months ended September 30, 2025, compared to $737,151 for the same period in 2024.
  • Net Cash Provided by Financing Activities: $16,055,985 for the nine months ended September 30, 2025, compared to $1,001,724 for the same period in 2024.

Unique Metrics

  • Convertible Notes with Warrants: The Notes, net of unamortized discount costs, were $6,507,354 as of September 30, 2025, compared to $5,406,228 as of December 31, 2024.
  • Warrants: As of September 30, 2025, 7,457,620 pre-funded warrants, 22,184,586 common warrants, and 443,692 placement agent warrants remain outstanding.

Future Outlook and Strategy

  • Core Business Focus: The company plans to finance its operations and commercial and development needs with its existing cash and cash equivalents, additional equity and/or debt financing arrangements, and revenue primarily anticipated from domestic sales of FemaSeed and FemVue and international sales of FemBloc, FemaSeed, and FemVue.
  • Non-Core Business: The company announced strategic distribution partnerships for FemBloc in Spain and France/Benelux region, respectively, and received FDA approval in November 2025 of its investigational device exemption (IDE) supplement to move forward to the final phase of the pivotal clinical trial for U.S. approval.
  • Priority: The company expects to continue to make substantial investments in its ongoing commercialization of its products and the pivotal trial designed to provide clinical evidence of the safety and effectiveness of its U.S. product candidate, FemBloc.
Source: LB filings The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer